{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:02:06Z","timestamp":1793394126640,"version":"4.5.0"},"reference-count":86,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Warm autoimmune hemolytic anemia (wAIHA) is caused by increased erythrocyte destruction by immunoglobulin G (IgG) autoantibodies, with or without complement activation. Antibody-dependent cell-mediated cytotoxicity by macrophages\/activated lymphocytes occurs in the lymphoid organs and spleen (extravascular hemolysis). The ability of the bone marrow (BM) to compensate determines clinical severity. The different pathogenic mechanisms, their complex interplay, and changes over time may explain wAIHA\u2019s great clinical heterogeneity and unpredictable course. The disease may be primary, drug induced, or associated with lymphoproliferative neoplasms, autoimmune and infectious diseases, immunodeficiencies, solid tumors, or transplants. Therapeutic interventions include steroids, splenectomy, immunosuppressants, and rituximab; the latter is increasingly used in steroid-refractory cases based on evidence from the literature and a few prospective trials. We present 5 patient case studies highlighting important issues: (1) the diagnosis and proper use of steroid therapy, (2) the concerns about the choice between rituximab and splenectomy in second-line treatment, (3) the need of periodical re-evaluation of the disease to assess the possible evolution of relapsed\/refractory cases in myelodysplastic and BM failure syndromes, and (4) the difficulties in managing cases of severe\/acute disease that are at high risk of relapse. Incorporating novel targeted therapies into clinical practice will be an exciting challenge in the future.<\/jats:p>","DOI":"10.1182\/blood.2019003808","type":"journal-article","created":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T22:05:06Z","timestamp":1611266706000},"page":"1283-1294","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":121,"title":["How I treat warm autoimmune hemolytic anemia"],"prefix":"10.1182","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1428-9944","authenticated-orcid":false,"given":"Wilma","family":"Barcellini","sequence":"first","affiliation":[{"name":"Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0857-8379","authenticated-orcid":false,"given":"Bruno","family":"Fattizzo","sequence":"additional","affiliation":[{"name":"Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy; and"},{"name":"Department of Oncology and Onco-hematology, University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2021031116253151200_B1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/bjh.14478","article-title":"The diagnosis and management of primary autoimmune haemolytic anaemia","volume":"176","author":"Hill","year":"2017","journal-title":"Br J Haematol"},{"issue":"5","key":"2021031116253151200_B2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1159\/000439002","article-title":"New insights in the pathogenesis of autoimmune hemolytic anemia","volume":"42","author":"Barcellini","year":"2015","journal-title":"Transfus Med Hemother"},{"issue":"6","key":"2021031116253151200_B3","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/17474086.2020.1754791","article-title":"Autoimmune hemolytic anemia in adults: primary risk factors and diagnostic procedures","volume":"13","author":"Barcellini","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"2021031116253151200_B4","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.3389\/fonc.2019.01435","article-title":"Autoimmune cytopenias in chronic lymphocytic leukemia: focus on molecular aspects","volume":"9","author":"Fattizzo","year":"2020","journal-title":"Front Oncol"},{"key":"2021031116253151200_B5","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/asheducation-2016.1.690","article-title":"Warm antibody autoimmune hemolytic anemia","volume":"2016","author":"Kalfa","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"22","key":"2021031116253151200_B6","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1182\/blood-2016-11-693689","article-title":"How I treat autoimmune hemolytic anemia","volume":"129","author":"Go","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2021031116253151200_B7","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1080\/1744666X.2018.1521722","article-title":"Current and emerging treatment options for autoimmune hemolytic anemia","volume":"14","author":"Barcellini","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"issue":"7","key":"2021031116253151200_B8","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMcp1900554","article-title":"Warm autoimmune hemolytic anemia","volume":"381","author":"Brodsky","year":"2019","journal-title":"N Engl J Med"},{"key":"2021031116253151200_B9","doi-asserted-by":"crossref","first-page":"100648","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting","volume":"41","author":"J\u00e4ger","year":"2020","journal-title":"Blood Rev"},{"issue":"16","key":"2021031116253151200_B10","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1182\/blood-2011-06-363556","article-title":"Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies","volume":"119","author":"Barcellini","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2021031116253151200_B11","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/bjh.12541","article-title":"A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia","volume":"163","author":"Birgens","year":"2013","journal-title":"Br J Haematol"},{"issue":"1","key":"2021031116253151200_B12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ajh.24570","article-title":"A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study)","volume":"92","author":"Michel","year":"2017","journal-title":"Am J Hematol"},{"key":"2021031116253151200_B13","doi-asserted-by":"crossref","first-page":"946","DOI":"10.3389\/fimmu.2020.00946","article-title":"The changing landscape of autoimmune hemolytic anemia","volume":"11","author":"Barcellini","year":"2020","journal-title":"Front Immunol"},{"key":"2021031116253151200_B14","volume-title":"Immune Hemolytic Anemias","author":"Petz","year":"2004","edition":"2nd ed"},{"key":"2021031116253151200_B15","doi-asserted-by":"crossref","first-page":"635670","DOI":"10.1155\/2015\/635670","article-title":"Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia","volume":"2015","author":"Barcellini","year":"2015","journal-title":"Dis Markers"},{"issue":"19","key":"2021031116253151200_B16","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1182\/blood-2014-06-583021","article-title":"Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients","volume":"124","author":"Barcellini","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2021031116253151200_B17","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/acr.23279","article-title":"2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"2021031116253151200_B18","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.autrev.2014.11.014","article-title":"Efficacy and safety of rituximab in auto-immune hemolytic anemia: a meta-analysis of 21 studies","volume":"14","author":"Reynaud","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"9","key":"2021031116253151200_B19","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1182\/blood-2018-12-885228","article-title":"Low-dose rituximab in autoimmune hemolytic anemia: 10 years after","volume":"133","author":"Fattizzo","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2021031116253151200_B20","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.amjsurg.2012.05.030","article-title":"Outcomes and complications after splenectomy for hematologic disorders","volume":"204","author":"Patel","year":"2012","journal-title":"Am J Surg"},{"issue":"9","key":"2021031116253151200_B21","doi-asserted-by":"crossref","first-page":"E150","DOI":"10.1002\/ajh.23767","article-title":"Characteristics and outcome of warm autoimmune hemolytic anemia in adults: new insights based on a single-center experience with 60 patients","volume":"89","author":"Roumier","year":"2014","journal-title":"Am J Hematol"},{"key":"2021031116253151200_B22","doi-asserted-by":"crossref","first-page":"102388","DOI":"10.1016\/j.bcmd.2019.102388","article-title":"Splenectomy and the incidence of venous thromboembolism and sepsis in patients with autoimmune hemolytic anemia","volume":"81","author":"Ho","year":"2020","journal-title":"Blood Cells Mol Dis"},{"issue":"8","key":"2021031116253151200_B23","doi-asserted-by":"crossref","first-page":"546","DOI":"10.7326\/0003-4819-151-8-200910200-00008","article-title":"Risk for hospital contact with infection in patients with splenectomy: a population-based cohort study","volume":"151","author":"Thomsen","year":"2009","journal-title":"Ann Intern Med"},{"issue":"2","key":"2021031116253151200_B24","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1046\/j.1365-2141.1996.4871026.x","article-title":"Long-term salvage treatment by cyclosporin in refractory autoimmune haematological disorders","volume":"93","author":"Emilia","year":"1996","journal-title":"Br J Haematol"},{"issue":"2","key":"2021031116253151200_B25","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood-2002-01-0087","article-title":"High-dose cyclophosphamide for refractory autoimmune hemolytic anemia","volume":"100","author":"Moyo","year":"2002","journal-title":"Blood"},{"issue":"3","key":"2021031116253151200_B26","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1365-2141.2002.03430.x","article-title":"Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura","volume":"117","author":"Howard","year":"2002","journal-title":"Br J Haematol"},{"issue":"7","key":"2021031116253151200_B27","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.autrev.2013.02.001","article-title":"Management of immune cytopenias in patients with systemic lupus erythematosus - old and new","volume":"12","author":"Newman","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"9","key":"2021031116253151200_B28","doi-asserted-by":"crossref","first-page":"E243","DOI":"10.1002\/ajh.25212","article-title":"Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from eight Italian reference centers","volume":"93","author":"Barcellini","year":"2018","journal-title":"Am J Hematol"},{"issue":"4","key":"2021031116253151200_B29","doi-asserted-by":"crossref","first-page":"E88","DOI":"10.1002\/ajh.25020","article-title":"Prognostic impact of bone marrow fibrosis and dyserythropoiesis in autoimmune hemolytic anemia","volume":"93","author":"Fattizzo","year":"2018","journal-title":"Am J Hematol"},{"issue":"11","key":"2021031116253151200_B30","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/ajh.23785","article-title":"Autoimmune cytopenias in chronic lymphocytic leukemia","volume":"89","author":"Visco","year":"2014","journal-title":"Am J Hematol"},{"issue":"2","key":"2021031116253151200_B31","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/leu.2015.273","article-title":"Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia","volume":"30","author":"Rogers","year":"2016","journal-title":"Leukemia"},{"issue":"9","key":"2021031116253151200_B32","first-page":"1273","article-title":"Rituximab in the treatment of refractory autoimmune cytopenias in adults","volume":"90","author":"Narat","year":"2005","journal-title":"Haematologica"},{"issue":"8","key":"2021031116253151200_B33","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ajh.20665","article-title":"Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia","volume":"81","author":"D\u2019Arena","year":"2006","journal-title":"Am J Hematol"},{"issue":"10","key":"2021031116253151200_B34","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/sj.leu.2402676","article-title":"Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia","volume":"16","author":"Gupta","year":"2002","journal-title":"Leukemia"},{"issue":"3","key":"2021031116253151200_B35","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/leu.2010.278","article-title":"Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia","volume":"25","author":"Rossignol","year":"2011","journal-title":"Leukemia"},{"issue":"4","key":"2021031116253151200_B36","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3109\/10428191003682767","article-title":"Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia\/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone","volume":"51","author":"Bowen","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2021031116253151200_B37","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1080\/10428190902887563","article-title":"A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia","volume":"50","author":"Kaufman","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2021031116253151200_B38","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/ajh.23909","article-title":"Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC\/MW and GOELAMS)","volume":"90","author":"Quinquenel","year":"2015","journal-title":"Am J Hematol"},{"issue":"3","key":"2021031116253151200_B39","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.leu.2404512","article-title":"Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody)","volume":"21","author":"Karlsson","year":"2007","journal-title":"Leukemia"},{"issue":"8","key":"2021031116253151200_B40","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1038\/sj.leu.2404703","article-title":"Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia","volume":"21","author":"Laurenti","year":"2007","journal-title":"Leukemia"},{"issue":"8","key":"2021031116253151200_B41","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1002\/1097-0142(20011015)92:8<2016::AID-CNCR1539>3.0.CO;2-E","article-title":"Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia","volume":"92","author":"Cortes","year":"2001","journal-title":"Cancer"},{"issue":"3","key":"2021031116253151200_B42","first-page":"237","article-title":"Role of splenectomy in chronic lymphocytic leukemia","volume":"185","author":"Cusack","year":"1997","journal-title":"J Am Coll Surg"},{"issue":"4","key":"2021031116253151200_B43","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.clml.2013.02.022","article-title":"Ofatumumab in rituximab-refractory autoimmune hemolytic anemia associated with chronic lymphocytic leukemia: a case report and review of literature","volume":"13","author":"Nader","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"2021031116253151200_B44","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1080\/10428194.2019.1702182","article-title":"Prolonged methylprednisolone premedication prior to obinutuzumab in patients with chronic lymphocytic leukemia","volume":"61","author":"Pejsa","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2021031116253151200_B45","doi-asserted-by":"crossref","first-page":"e524","DOI":"10.1038\/bcj.2017.5","article-title":"Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study [letter]","volume":"7","author":"Montillo","year":"2017","journal-title":"Blood Cancer J"},{"key":"2021031116253151200_B46","article-title":"Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia (ISRAEL)","author":"US National Library of Medicine:"},{"issue":"9","key":"2021031116253151200_B47","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00277-017-3039-1","article-title":"Treatment of refractory autoimmune hemolytic anemia with venetoclax in relapsed chronic lymphocytic leukemia with del(17p)","volume":"96","author":"Lacerda","year":"2017","journal-title":"Ann Hematol"},{"issue":"11","key":"2021031116253151200_B48","doi-asserted-by":"crossref","first-page":"e0207218","DOI":"10.1371\/journal.pone.0207218","article-title":"Venous thromboembolic events during warm autoimmune hemolytic anemia","volume":"13","author":"Audia","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"2021031116253151200_B49","doi-asserted-by":"crossref","first-page":"325","DOI":"10.7326\/0003-4819-102-3-325","article-title":"Splenectomy does not cure the thrombocytopenia of systemic lupus erythematosus","volume":"102","author":"Hall","year":"1985","journal-title":"Ann Intern Med"},{"issue":"1","key":"2021031116253151200_B50","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2018-11-887141","article-title":"Pediatric Evans syndrome is associated with a high frequency of potentially damaging variants in immune genes","volume":"134","author":"Hadjadj","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2021031116253151200_B51","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1053\/j.seminhematol.2005.04.004","article-title":"The changing spectrum of drug-induced immune hemolytic anemia","volume":"42","author":"Arndt","year":"2005","journal-title":"Semin Hematol"},{"issue":"4","key":"2021031116253151200_B52","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1517\/14740338.2012.678832","article-title":"Immune hemolytic anemia caused by drugs","volume":"11","author":"Garratty","year":"2012","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"2021031116253151200_B53","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.leukres.2013.09.001","article-title":"Increased prevalence of autoimmune phenomena in myelofibrosis: relationship with clinical and morphological characteristics, and with immunoregulatory cytokine patterns","volume":"37","author":"Barcellini","year":"2013","journal-title":"Leuk Res"},{"issue":"8","key":"2021031116253151200_B54","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1111\/trf.13652","article-title":"Detection of erythroblast antibodies in mitogen-stimulated bone marrow cultures from patients with myelodysplastic syndromes","volume":"56","author":"Zaninoni","year":"2016","journal-title":"Transfusion"},{"issue":"1","key":"2021031116253151200_B55","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000489042","article-title":"ICUS, IDUS, CHIP and CCUS: diagnostic criteria, separation from MDS and clinical implications","volume":"86","author":"Valent","year":"2019","journal-title":"Pathobiology"},{"issue":"14","key":"2021031116253151200_B56","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1182\/blood.2020005293","article-title":"Does clonal hematopoiesis explain unexplained anemia?","volume":"135","author":"Steensma","year":"2020","journal-title":"Blood"},{"issue":"7","key":"2021031116253151200_B57","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1080\/17474086.2017.1339597","article-title":"The relationship between idiopathic cytopenias\/dysplasias of uncertain significance (ICUS\/IDUS) and autoimmunity","volume":"10","author":"Barcellini","year":"2017","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"2021031116253151200_B58","doi-asserted-by":"crossref","first-page":"E26","DOI":"10.1002\/ajh.24618","article-title":"Clinical evolution of autoimmune cytopenias to idiopathic cytopenias\/dysplasias of uncertain significance (ICUS\/IDUS) and bone marrow failure syndromes","volume":"92","author":"Barcellini","year":"2017","journal-title":"Am J Hematol"},{"key":"2021031116253151200_B59","article-title":"Efficacy of recombinant erythropoietin in autoimmune haemolytic anaemia: a multicentre international study [published online ahead of print 30 April 2020]","author":"Fattizzo","journal-title":"Haematologica"},{"issue":"3","key":"2021031116253151200_B60","doi-asserted-by":"crossref","first-page":"298","DOI":"10.7326\/0003-4819-102-3-298","article-title":"Danazol therapy for autoimmune hemolytic anemia","volume":"102","author":"Ahn","year":"1985","journal-title":"Ann Intern Med"},{"issue":"2","key":"2021031116253151200_B61","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2141.1993.tb08293.x","article-title":"Danazol in autoimmune haemolytic anaemia","volume":"83","author":"Pignon","year":"1993","journal-title":"Br J Haematol"},{"issue":"20","key":"2021031116253151200_B62","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1056\/NEJMoa1515319","article-title":"Danazol treatment for telomere diseases","volume":"374","author":"Townsley","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"2021031116253151200_B63","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1080\/10245332.2016.1138621","article-title":"Clinical characteristics and long-term outcomes of warm-type autoimmune hemolytic anemia","volume":"21","author":"Rattarittamrong","year":"2016","journal-title":"Hematology"},{"issue":"8","key":"2021031116253151200_B64","doi-asserted-by":"crossref","first-page":"E149","DOI":"10.1002\/ajh.24047","article-title":"Lessons from very severe, refractory, and fatal primary autoimmune hemolytic anemias","volume":"90","author":"Fattizzo","year":"2015","journal-title":"Am J Hematol"},{"issue":"3","key":"2021031116253151200_B65","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00277-018-3553-9","article-title":"Prognosis of autoimmune hemolytic anemia in critically ill patients","volume":"98","author":"Lafarge","year":"2019","journal-title":"Ann Hematol"},{"issue":"15","key":"2021031116253151200_B66","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood-2009-04-215368","article-title":"The spectrum of Evans syndrome in adults: new insight into the disease based on the analysis of 68 cases","volume":"114","author":"Michel","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2021031116253151200_B67","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bbmt.2014.09.009","article-title":"Autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: analysis of 533 adult patients who underwent transplantation at King\u2019s College Hospital","volume":"21","author":"Wang","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021031116253151200_B68","article-title":"Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (HSCT): a retrospective analysis and a proposal of treatment on behalf of the Grupo Espa\u00f1ol De Trasplante de Medula Osea en Ni\u00f1os (GETMON) and the Grupo Espa\u00f1ol de Trasplante Hematopoyetico (GETH) [published online ahead of print 3 March 2018]","author":"Gonz\u00e1lez-Vicent","journal-title":"Transfus Med Rev"},{"issue":"4","key":"2021031116253151200_B69","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.bbmt.2017.12.782","article-title":"Risk factors, treatment, and immune dysregulation in autoimmune cytopenia after allogeneic hematopoietic stem cell transplantation in pediatric patients","volume":"24","author":"Kruizinga","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021031116253151200_B70","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2147\/JBM.S190327","article-title":"Management of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: current perspectives","volume":"10","author":"Barcellini","year":"2019","journal-title":"J Blood Med"},{"issue":"4","key":"2021031116253151200_B71","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/ajh.2830440404","article-title":"Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients","volume":"44","author":"Flores","year":"1993","journal-title":"Am J Hematol"},{"key":"2021031116253151200_B72","article-title":"A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia","author":"US National Library of Medicine:"},{"key":"2021031116253151200_B73","article-title":"Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients with Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)","author":"US National Library of Medicine:"},{"key":"2021031116253151200_B74","article-title":"A Safety Study of SYNT001 in Participants with Warm Autoimmune Hemolytic Anemia (WAIHA)","author":"US National Library of Medicine:"},{"key":"2021031116253151200_B75","article-title":"ALXN1830 in Patients with Warm Autoimmune Hemolytic Anemia","author":"US National Library of Medicine:"},{"key":"2021031116253151200_B76","article-title":"Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia","author":"US National Library of Medicine:"},{"key":"2021031116253151200_B77","article-title":"A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA) (SOAR)","author":"US National Library of Medicine:"},{"key":"2021031116253151200_B78","article-title":"A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA","author":"US National Library of Medicine:"},{"key":"2021031116253151200_B79","article-title":"Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia (RRAIHA01)","author":"US National Library of Medicine:"},{"key":"2021031116253151200_B80","article-title":"Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment (ANEMIL)","author":"US National Library of Medicine:"},{"issue":"19","key":"2021031116253151200_B81","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1182\/bloodadvances.2018020883","article-title":"Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation","volume":"2","author":"Schuetz","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"2021031116253151200_B82","doi-asserted-by":"crossref","first-page":"e28010","DOI":"10.1002\/pbc.28010","article-title":"Successful treatment with daratumumab for post-HSCT refractory hemolytic anemia","volume":"67","author":"Even-Or","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2021031116253151200_B83","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/petr.12101","article-title":"Refractory autoimmune hemolytic anemia after intestinal transplant responding to conversion from a calcineurin to mTOR inhibitor","volume":"17","author":"Acquazzino","year":"2013","journal-title":"Pediatr Transplant"},{"issue":"9","key":"2021031116253151200_B84","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1111\/trf.14907","article-title":"Successful treatment of severe refractory autoimmune hemolytic anemia after hematopoietic stem cell transplant with abatacept","volume":"58","author":"Hess","year":"2018","journal-title":"Transfusion"},{"issue":"24","key":"2021031116253151200_B85","doi-asserted-by":"crossref","first-page":"5080","DOI":"10.1182\/blood-2009-08-239020","article-title":"The IgG-specific endoglycosidase EndoS inhibits both cellular and complement-mediated autoimmune hemolysis","volume":"115","author":"Allhorn","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2021031116253151200_B86","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1097\/TP.0000000000003023","article-title":"Imlifidase inhibits HLA antibody-mediated NK cell activation and antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro","volume":"104","author":"Ge","year":"2020","journal-title":"Transplantation"}],"updated-by":[{"DOI":"10.1182\/blood.2022019024","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000}}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/10\/1283\/1802426\/bloodbld2019003808c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/10\/1283\/1802426\/bloodbld2019003808c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T16:26:27Z","timestamp":1615479987000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/10\/1283\/475030\/How-I-treat-warm-autoimmune-hemolytic-anemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,11]]},"references-count":86,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,3,11]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019003808","relation":{"erratum":[{"id-type":"doi","id":"10.1182\/blood.2022019024","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,11]]}}}